Literature DB >> 29545660

Anti-diabetic medications: How to make a choice?

Amir Babiker1, Mohammed Al Dubayee1.   

Abstract

Diabetes is the third commonest chronic illness in children following asthma and epilepsy. More recently the overall prevalence of diabetes in children and adults continued to increase dramatically. In children, this has partially been contributed to by the pandemic of obesity. Understandably, this posed an economic burden on health authorities and countries dealing with significant morbidity of the disease with potentially serious complications. In parallel to this, more therapeutic discoveries expanded the list of choice for available medications. We hypothesize that specialist clinicians are requested by an authority to submit a report of prioritization for anti-diabetic drugs. The authority new policy is to purchase for only three of anti-diabetic medications among a long list of old and new drugs. We gave a recommendation here in response to this request based on different properties of these medications and also based on the largest known clinical trials in the field. Some may have a different choice for a third medication besides insulin and metformin and physicians in many clinical settings may have a choice of more than three at a time. However, we, at least, provide here a thorough review of these drugs, their mechanistic of action, benefits and side effects to facilitate a better choice for individual patients according to underlying pathophysiological cause, other medical needs and tolerance to different medications. Paediatricians are increasingly managing adolescents with type 2 diabetes these days. Hence, we wrote this review as a quick reference guide to anti-diabetic medications to which they might be less familiar.

Entities:  

Keywords:  Classes; diabetes; glucose; hyperglycaemia; incretin; insulin; medications; metformin.

Year:  2017        PMID: 29545660      PMCID: PMC5845451          DOI: 10.24911/SJP.2017.2.12

Source DB:  PubMed          Journal:  Sudan J Paediatr        ISSN: 0256-4408


  35 in total

1.  Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  S E Inzucchi; R M Bergenstal; J B Buse; M Diamant; E Ferrannini; M Nauck; A L Peters; A Tsapas; R Wender; D R Matthews
Journal:  Diabetologia       Date:  2012-04-20       Impact factor: 10.122

2.  Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury.

Authors:  Amal K Bose; Mihaela M Mocanu; Richard D Carr; Christian L Brand; Derek M Yellon
Journal:  Diabetes       Date:  2005-01       Impact factor: 9.461

Review 3.  Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications.

Authors:  Richard M Bergenstal; Clifford J Bailey; David M Kendall
Journal:  Am J Med       Date:  2010-04       Impact factor: 4.965

4.  United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.

Authors: 
Journal:  Ann Intern Med       Date:  1998-02-01       Impact factor: 25.391

5.  Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

Authors:  Bernard Charbonnel; Avraham Karasik; Ji Liu; Mei Wu; Gary Meininger
Journal:  Diabetes Care       Date:  2006-12       Impact factor: 19.112

Review 6.  Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations.

Authors:  Wendy L Bennett; Nisa M Maruthur; Sonal Singh; Jodi B Segal; Lisa M Wilson; Ranee Chatterjee; Spyridon S Marinopoulos; Milo A Puhan; Padmini Ranasinghe; Lauren Block; Wanda K Nicholson; Susan Hutfless; Eric B Bass; Shari Bolen
Journal:  Ann Intern Med       Date:  2011-03-14       Impact factor: 25.391

7.  beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis.

Authors:  Ele Ferrannini; Amalia Gastaldelli; Yoshinori Miyazaki; Masafumi Matsuda; Andrea Mari; Ralph A DeFronzo
Journal:  J Clin Endocrinol Metab       Date:  2004-10-13       Impact factor: 5.958

8.  UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance.

Authors: 
Journal:  Diabetologia       Date:  1991-12       Impact factor: 10.122

9.  Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.

Authors:  Y Ohkubo; H Kishikawa; E Araki; T Miyata; S Isami; S Motoyoshi; Y Kojima; N Furuyoshi; M Shichiri
Journal:  Diabetes Res Clin Pract       Date:  1995-05       Impact factor: 5.602

10.  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Authors:  Philip D Home; Stuart J Pocock; Henning Beck-Nielsen; Paula S Curtis; Ramon Gomis; Markolf Hanefeld; Nigel P Jones; Michel Komajda; John J V McMurray
Journal:  Lancet       Date:  2009-06-06       Impact factor: 79.321

View more
  6 in total

1.  Inauguration of another pyramid: the Sudan Childhood Diabetes Center.

Authors:  Mustafa Abdalla M Salih; Mohammed Osman Swar
Journal:  Sudan J Paediatr       Date:  2019

2.  Baseline Characteristics Associated With Sodium-Glucose Cotransporter Inhibitor Prescriptions in Type 2 Diabetic Patients in Jazan, Saudi Arabia.

Authors:  Mohammed Somaili; Omar Oraibi; Mostafa Mohrag; Abdelrahman Hommadi; Esam Moafa; Abdulrahman Kulaybi; Sahar Shobayli; Razan Moafa; Ghadah Mhgfory; Afaf Jaafari; Ayman Shami; Khalid Majrashi
Journal:  Cureus       Date:  2022-04-19

3.  Defining Disease Progression and Drug Durability in Type 2 Diabetes Mellitus.

Authors:  Sanjay Kalra; Nor Azmi Kamaruddin; Jayanti Visvanathan; Ravi Santani
Journal:  Eur Endocrinol       Date:  2019-08-16

Review 4.  Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes.

Authors:  Qiming Tan; Seun E Akindehin; Camila E Orsso; Richelle C Waldner; Richard D DiMarchi; Timo D Müller; Andrea M Haqq
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-01       Impact factor: 5.555

5.  Safety Assessment of Glucose-Lowering Drugs and Importance of Structured Education during Ramadan: A Systematic Review and Meta-Analysis.

Authors:  Rashmi Shiju; Ayesha Akhil; Smitha Thankachan; Jaakko Tuomilehto; Monira Al Arouj; Abdullah Bennakhi
Journal:  J Diabetes Res       Date:  2022-02-18       Impact factor: 4.011

6.  Towards the Pharmacological Validation and Phytochemical Profiling of the Decoction and Maceration of Bruguiera gymnorhiza (L.) Lam.-A Traditionally Used Medicinal Halophyte.

Authors:  Nabeelah Bibi Sadeer; Kouadio Ibrahime Sinan; Zoltán Cziáky; József Jekő; Gokhan Zengin; Rajesh Jeewon; Hassan H Abdallah; Yusra AlDhaheri; Ali H Eid; Mohamad Fawzi Mahomoodally
Journal:  Molecules       Date:  2022-03-20       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.